康希諾(688185.SH):在研產品管線中的早期候選產品初步應用合成生物學相關技術
格隆匯5月13日丨康希諾(688185.SH)在投資者互動平台表示,公司在研產品管線中的早期候選產品初步應用合成生物學相關技術,未來會進一步評估相關進展及優勢;PBPV作為一款全球創新疫苗,該產品的對外合作也是公司全球戰略佈局的重要一環,因此公司也在全球範圍內尋找潛在合作方,包括擁有科研實力、資源和資金的國際知名企業等,希望能夠更快地推進該產品的研發進度,如有階段性進展,會及時分享。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.